Zydus receives final approval from the USFDA for Ivermectin Cream
Drug Approval

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.

  • By IPP Bureau | August 04, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ivermectin Cream, 1%. USRLD: Soolantra.

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea. The drug will be manufactured at the group's topical manufacturing facility at Ahmedabad, India.

Ivermectin Cream had annual sales of USD 176 million in the United States according to IQVIA data (IQVIA MAT June 2022).

The group now has 319 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

Upcoming E-conference

Other Related stories

Startup

Digitization